LimmaTech raises $37 million for vaccine pipeline

Swiss biotech LimmaTech Biologics has announced the closing of a $37 million Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.

The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea.

"We look forward to providing life-changing vaccines"Later-stage clinical development efforts will focus on the company’s Shigella vaccine program, which LimmaTech developed as part of a joint collaboration with UK pharma major GSK (LSE: GSK) and recently exclusively in-licensed.